Our professionals
Dr. Bruno Sangro
Director of the Hepatology Unit.
Specialist in Internal Medicine.
Special focus on the study and treatment of liver diseases and tumors of the liver and biliary tract.
Professional career
Graduated in Medicine from the Complutense University of Madrid (1983). PhD in Medicine from the University of Navarra (1994).
Specialist in Internal Medicine (1990).
Director of the Hepatology Unit in the Department of Internal Medicine at Clínica Universidad de Navarra.
RESEARCH AREAS
Principal Investigator of Group 6 at the Biomedical Research Network Center for Liver and Digestive Diseases (CIBERehd).
His translational and clinical research over the years has focused on innovations in the treatment of primary and secondary liver tumors and complications of cirrhosis. In particular, he has worked on developing a multidisciplinary liver cancer treatment program that incorporates innovations in surgery (expanded criteria for liver transplantation and resection in selected patients with portal hypertension), intra-arterial techniques (chemoembolization and radioembolization), and systemic treatment (advanced therapies such as immunotherapy and gene therapy).
AREAS OF INTEREST
- Study and treatment of liver tumors.
- Study and treatment of biliary tract tumors.
- Study and treatment of liver diseases.
Activity
In teaching
Professor of Internal Medicine at the University of Navarra.
In research
He has coauthored 20 chapters in specialist books, published more than 400 articles in national and international journals, and supervised 14 doctoral theses.

Acknowledgement
- In September 2019 he has been appointed President of the International Liver Cancer Association (ILCA).
Scientific organizations
- Member of the Executive Committee of the International Liver Cancer Association (ILCA).
- Founding member and member of the board of directors of the Spanish Society of Gene Therapy.
- Spanish Association for the Study of the Liver.
- European Association for the Study of the Liver.
Latest scientific publications
- Ultra-low-pass whole-genome sequencing of bile cfDNA in patients with biliary strictures Jul 31, 2026 | Magazine: eGastroenterology
- Histone methyl-transferase G9a inhibition boosts the efficacy of immune checkpoint inhibitors in experimental hepatocellular carcinoma [SP] Apr 21, 2026 | Magazine: Cell Reports Medicine